Aslan Pharmaceuticals Ltd (ASLN)

What analysts predicted

Upside of 11900.0%

• Bvf Inc

  4.64%

• Velan Capital Investment Management LP

  2.76%

• Shay Capital LLC

  1.77%

• Sio Capital Management, LLC

  1.12%

• Schonfeld Strategic Advisors LLC

  0.65%

• Renaissance Technologies Corp

  0.54%

aslan pharmaceuticals (aslan, 6497.tt) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. aslan targets diseases that are both highly prevalent in asia and orphan indications in the united states and europe. led by a senior management team with extensive experience in global and regional development and commercialization, aslan is headquartered in singapore and has offices in taiwan and china. aslan’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. aslan’s partners include array biopharma, bristol-myers squibb, almirall and csl.